OA
IBB icon

Oxbow Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Oxbow Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,075
Closed -$825K – 233
2023
Q4 		$825K Hold
6,075
– – 0.13% 95
2023
Q3 		$743K Hold
6,075
– – 0.12% 93
2023
Q2 		$771K Buy
6,075
+1,200
+25% +$156K 0.12% 96
2023
Q1 		$630K Buy
4,875
+2,000
+70% +$262K 0.11% 112
2022
Q4 		$377K Sell
2,875
-2,875
-50% -$372K 0.07% 152
2022
Q3 		$673K Hold
5,750
– – 0.11% 133
2022
Q2 		$676K Buy
5,750
+1,100
+24% +$131K 0.1% 134
2022
Q1 		$606K Buy
4,650
+1,550
+50% +$202K 0.06% 162
2021
Q4 		$473K Buy
+3,100
New +$480K 0.05% 193

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Oxbow Advisors's IBB Position: Q1 2024 in Review

Oxbow Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2024, closing a stake of 6,075 shares — an estimated $825K sold.

Oxbow Advisors first reported a position in IBB in Q4 2021 and held it in 9 quarters. The position peaked at $825K in Q4 2023. 899 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

  • Oxbow Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2024 after selling out during the quarter.
  • Oxbow Advisors sold 6,075 iShares Biotechnology ETF shares in Q1 2024, an estimated $825K.
  • Oxbow Advisors first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 9 quarters.
  • Oxbow Advisors's iShares Biotechnology ETF position peaked at $825K in Q4 2023.
  • 899 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Oxbow Advisors's 13F filing for Q1 2024, filed 6 May 2024.